Key points from article :
An Israeli startup, ForSight Robotics, is aiming to revolutionize cataract surgery using a robotic platform named Oryom, designed specifically for eye operations. Cataract surgery is one of the world’s most common procedures, but a global shortage of ophthalmologists leaves millions untreated. ForSight believes that its robotic solution—now being tested on pig eyes and preparing for its first human surgery—can address this shortage by performing faster, more precise, and cost-effective operations.
The company recently secured $125 million in Series B funding, led by Eclipse Ventures and joined by surgical robotics pioneer Fred Moll, bringing its total funding to $195 million and valuing the company at around $500 million. The technology combines microsurgical robots with AI-driven computer vision, allowing for highly repetitive and delicate procedures like cataract surgery to be performed with minimal error and high consistency. ForSight is currently in early discussions with the U.S. FDA and plans to begin collecting human clinical data soon.
Founded in 2020 by surgeon Dr. Joseph Nathan, robotics professor Moshe Shoham, and former Medtronic executive Daniel Glozman, ForSight draws from Israel’s strong medical device innovation ecosystem. The company hopes to expand beyond cataract surgeries to more complex eye conditions like retinal repairs and glaucoma treatments. With demand for eye surgeries expected to soar and too few specialists to meet the need—especially in countries like India—ForSight envisions its robots playing a vital role in closing this healthcare gap.
Dr. Nathan sees a future where surgical robotics not only enhance outcomes but also dramatically improve global access to sight-saving procedures. “There is no human way to close the gap as we see it,” he said, emphasizing the urgency and potential impact of robotic intervention in ophthalmology.
